Skip to contentC
Cartesian Therapeutics, Inc.
C
RNACCartesian Therapeutics, Inc. Q2 2021 · 10-Q
Revenue$19.66M$19.66M— vs Q2 2020 Net Income$4.57M$4.57MN/M vs Q2 2020 EPS Diluted$0.00$0.00N/M vs Q2 2020 Operating Income$452,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cartesian Therapeutics, Inc. · CIK 1453687 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$6,661,000N/M Margins · derivedOperating margin2.3%
Net margin23.2%
ended Jun 30, 2021 · filed Aug 12, 2021 · 43 d after period end